Full oral vinorelbine (NVBO) on D1 and D8 with carboplatin (CBDCA) as first line treatment in advanced non-small lung cancer (NSCLC) patients: Results of a prospective study in nonrandomized population of 259 patients

The purpose of this trial was to evaluate the activity and feasibility of CBDCA together with full oral vinorelbin (NVBO) in 1st line treatment NSCLC patients. This is a prospective nerandomizovanou study of 259 patients.This is a prospective nerandomizovanou study of 259 patients.